Titre :

Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Auteur(s) :

Chamcheu, Jean Christopher [Auteur]
Louisiana State University [LSU]
Siddiqui, Imtiaz A [Auteur]
Adhami, Vaqar M [Auteur]
Esnault, Stéphane [Auteur]
University of Wisconsin School of Medicine and Public Health
Bharali, Dhruba J [Auteur]
Babatunde, Abiola S [Auteur]
Adame, Stephanie [Auteur]
Massey, Randall J [Auteur]
Wood, Gary S [Auteur]
Longley, B Jack [Auteur]
Mousa, Shaker A [Auteur]
Mukhtar, Hasan [Auteur]

Titre de la revue :

International Journal of Nanomedicine

Nom court de la revue :

Int J Nanomedicine

Numéro :

13

Pagination :

4189-4206

Éditeur :

Dove Medical Press

Date de publication :

2018-07-20

Statut de l’article :

Publié

ISSN :

1178-2013

Mot(s)-clé(s) en anglais :

Administration, Topical
Aminoquinolines
Animals
Antineoplastic Agents
Antioxidants
Catechin
Cell Differentiation
Cells, Cultured
Chitosan
Dermatitis
Filaggrin Proteins
Humans
Imiquimod
Keratinocytes
Mice
Mice, Inbred BALB C
Nanoparticles
Psoriasis
anti-inflammatory action
chitosan nanoparticles
differentiation
normal human epidermal keratinocytes
phytochemical treatment of psoriasis
psoriasis-like skin inflammation
topical delivery of chitosan nanoformulated EGCG

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents ...
Lire la suite >Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents that can abrogate these effects could be useful for the treatment of psoriasis. Earlier studies have shown that treatment of keratinocytes and mouse skin with the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) mitigated inflammation and increased the expression of caspase-14 while promoting epidermal differentiation and cornification. However, bioavailability issues have restricted the development of EGCG for the treatment of psoriasis. To overcome these limitations, we employed a chitosan-based polymeric nanoparticle formulation of EGCG (CHI-EGCG-NPs, hereafter termed nanoEGCG) suitable for topical delivery for treating psoriasis. We investigated and compared the efficacy of nanoEGCG versus native or free EGCG in vitro and in an in vivo imiquimod (IMQ)-induced murine psoriasis-like dermatitis model. The in vivo relevance and efficacy of nanoEGCG formulation (48 µg/mouse) were assessed in an IMQ-induced mouse psoriasis-like skin lesion model compared to free EGCG (1 mg/mouse). Like free EGCG, nanoEGCG treatment induced differentiation, and decreased proliferation and inflammatory responses in cultured keratinocytes, but with a 4-fold dose advantage. Topically applied nanoEGCG elicited a significant (20-fold dose advantage over free EGCG. Based on these observations, our nanoEGCG formulation represents a promising drug-delivery strategy for treating psoriasis and possibly other inflammatory skin diseases.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Autres travaux scientifiques

Date de dépôt :

2023-10-23T11:29:32Z
2024-05-23T11:16:01Z